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Case Report
Introduction
Primary gastrointestinal (GI) lymphoma is a heterogeneous 
disease.1 Its clinical presentation varies depending on the loca-
tion of the disease in the GI tract, staging, and histologic sub-
types.1 The stomach is the most common extranodal site and 
accounts for 70% to 75% of GI lymphomas.1,2 The majority of 
cases (~90%) with gastric lymphoma are either of the follow-
ing 2 subtypes: (a) extranodal marginal zone B cell lymphoma 
of mucosa-associated lymphoid tissue (MALT) or (b) diffuse 
large B cell lymphoma (DLBCL).1,2 MALT lymphomas arise 
from post–germinal center memory B cells and are related to 
chronic immune reactions driven by infections such as 
Helicobacter pylori or other autoimmune stimuli.3-6 DLBCL is 
the most common histologic subtype of non-Hodgkin disease.7 
Patients with DLBCL typically present with a rapidly enlarging 
symptomatic mass, usually manifested as a nodal enlargement 
in the neck or abdomen. However, extranodal disease is not 
uncommon.7,8 We highlight a patient with gastric DLBCL who 
presented with significant weight loss and multifocal ulcerated 
gastric lesions. The objective of this case report is to increase 
cognizance for the detection of gastric DLBCL.
Case Report
An 82-year-old male presented with progressive weakness, 
early satiety, and failure to thrive. He experienced an 
80-pound unintentional weight loss in the past 3.5 years, 
with 34 pounds in the past 8 months. His last colonoscopy 2 
years ago showed small tubular adenomas. Physical exami-
nation was unremarkable except for cachexia and pallor. 
Baseline labs were as follows: white blood cell count 4600/
µL, hemoglobin 8.5 g/dL, hematocrit 25%, mean corpuscu-
lar volume 95.8 fL, platelet count 169 000/µL, blood urea 
nitrogen 41 mg/dL, creatinine 1.8 mg/dL, total bilirubin 
0.24 mg/dL, aspartate transaminase 10 U/L, alanine trans-
aminase 16 U/L, alkaline phosphatase 114 U/L, albumin 3.6 
g/dL, total protein 5.8 g/dL, lactate dehydrogenase 118 U/L, 
iron 92 µg/dL, ferritin 87 ng/mL, iron saturation 35%, posi-
tive stool occult blood, folate 8.7 ng/mL, and vitamin B
12
 
490 pg/mL. A chest computed tomography (CT) was unre-
markable. An abdominal CT showed mild fat stranding as 
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Abstract
Primary gastrointestinal (GI) lymphoma is a heterogeneous disease with varied clinical presentations. The stomach is the 
most common GI site and accounts for 70% to 75% of GI lymphomas. We present a patient with gastric diffuse large B 
cell lymphoma (DLBCL) who presented with significant weight loss, early satiety, and multifocal ulcerated gastric lesions. 
Esophagoduodenoscopy should be performed in patients presenting with warning symptoms as in our case. Diagnosis is 
usually made by endoscopic biopsies. Multiple treatment modalities including surgery, radiotherapy, and chemotherapy have 
been used. Advancements in endoscopic and pathologic technology decrease turnaround time for diagnosis and treatment 
initiation, thus reducing the need for surgery. Health care providers should maintain a high level of suspicion and consider 
gastric DLBCL as part of the differential diagnosis, especially in those with warning symptoms such as weight loss and early 
satiety with abnormal endoscopic findings.
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Figure 3. Immunohistochemistry showed that these atypical 
lymphocytes are positive for Pax-5 (shown) and CD20 (not 
shown), indicating a B lymphocyte lineage.
well as minimal fluid surrounding the ascending colon 
without any evidence of intraabdominal lymphadenopathy. 
He underwent an esophagogastroduodenoscopy (EGD) to 
investigate the cause for significant weight loss and early 
satiety. EGD demonstrated multiple ulcerated gastric lesions 
in the fundus and body (Figure 1). The antrum was charac-
terized by mild erythematous gastropathy. Additionally, no 
sites of active bleeding were found. The ulcerated lesions 
and the uninvolved antrum/incisura were biopsied. 
Histopathology revealed ulcerated mucosa with atypical 
lymphoid infiltrations, characterized by large lympho-
cytes with irregular nuclei, distinct nucleoli, vesicular 
chromatin, and evident mitoses and apoptosis (Figure 2). 
Immunohistochemistry was positive for cluster of differen-
tiation (CD) 45, CD20, paired box 5 (PAX-5; Figure 3), and 
B-cell lymphoma 6 (BCL-6) and negative for cytokeratin 
and melanoma associated antigen (mutated) 1 (MUM-1). 
Ki-67 showed a high proliferative index (80%). The gastric 
biopsies from the nonulcerated mucosa in the antrum/inci-
sura demonstrated inflammatory cells consistent with gas-
tritis, and immunohistochemistry was negative for 
Helicobacter pylori. The findings are consistent with 
DLBCL, stage 1E. Gastrectomy was not pursued due to his 
frailty and advanced age. He was initiated on abbreviated 
chemotherapy with subsequent involved field radiation. An 
attenuated immunochemotherapy regimen (R-miniCHOP; 
rituximab, cyclophosphamide, doxorubicin, vincristine, and 
prednisone9) was started. He tolerated chemotherapy but 
presented with coffee-ground emesis, after completing 3 
cycles of chemotherapy. EGD noted a bleeding ulcer, which 
was treated endoscopically. There was notable improvement 
in DLBCL-related ulcers compared to previous EGD (Figure 
4A and B). He had no recurrent bleeding and subsequently 
underwent involved field radiation.
Discussion
DLBCL is the most common lymphoma, accounting for 25% 
of all non-Hodgkin cases.7 In the elderly (75 years or older), 
rates of DLBCL increase 1.4% per year.10 The molecular 
pathogenesis of DLBCL is a complex, multistep process that 
ultimately results in the transformation and expansion of a 
malignant clone of germinal or post–germinal B cells.7 
Several genetic changes involving BCL-6 and p53 tumor 
suppressor genes have been found in DLBCL.11-13
Figure 1. Multifocal ulcerations in gastric body and fundus 
(arrow), with surrounding diffuse erythema (arrowhead).
Figure 2. Hematoxylin-eosin section demonstrated ulcerated 
mucosa with diffuse atypical lymphocytic infiltration effacing gastric 
architecture. These atypical lymphocytes are large with distinct 
nucleolus, vesicular chromatin, and increased apoptosis (inset).
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Patients with DLBCL typically present with rapidly 
enlarging lymph nodes in the neck or abdomen. Fever, 
weight loss, and night sweats are not uncommon and can be 
observed in up to 30% of patients.14 Extranodal disease can 
occur in up to 40% of cases with the stomach being the most 
common site.8 In general, patients with gastric DLBCL 
present with nonspecific symptoms, including epigastric 
discomfort, unexplained weight loss, anorexia, vomiting, 
and occult bleeding.1,15 Hematemesis and melena are 
uncommon. Additionally, the duration of symptoms preced-
ing the diagnosis is varied.16 Diagnosis is usually made by 
endoscopic biopsies. The endoscopic findings of DLBCL 
may include mucosal erythema, gastric ulcer, polypoid mass 
lesion, and/or thickened gastric folds.17 It is recommended 
that both suspicious-appearing as well as normal-appearing 
mucosa be biopsied since the disease can occasionally pres-
ent as a multifocal disease with involvement of tissue that 
appears to be unaffected on initial visualization.16,18 Gastric 
wall thickening can be found on radiographic imaging such 
as CT scan, though this was not observed in our case.19
Histopathology of DLBCL consists of large, transformed 
B cells with prominent nucleoli, basophilic cytoplasm, a diffuse 
growth pattern, and a high proliferation fraction (Figure 2).20 
The immunophenotype of DLBCL can be confirmed by 
immunohistochemistry or flow cytometry (Figure 3). Gastric 
lymphoma is less common than gastric cancer but has a more 
favorable prognosis. Rather than the classic Ann Arbor lym-
phoma staging criteria, the TNM staging system provides a 
more accurate prognosis since gastric DLBCL starts locally 
before spreading to the locoregional lymph nodes prior to dis-
tant metastasis, which occurs once the tumor invades into 
submucosal tissue.21 Multiple treatment modalities including 
surgery, radiotherapy, and chemotherapy have been used. 
Published reports are based on a limited heterogeneous 
patient population and, thus, do not allow for comparison of 
success rates among treatment options. In the past, surgery 
has been a commonly used modality as it provides rapid 
symptom control, tissue diagnosis, accurate pathological 
staging, and can also be curative therapy in patients with early 
stage disease (IE and IIE),22 but associated surgical complica-
tions makes it less suitable for frail individuals. Gastrectomy, 
gastrectomy with adjuvant radiation, and gastrectomy with 
adjuvant chemotherapy were compared to chemotherapy 
alone in a small controlled study.23 Ten-year overall survival 
data favored chemotherapy due to the acute and long-term 
complications of total gastrectomy.23 Advancements in endo-
scopic and pathologic technology decrease turnaround time 
for diagnosis and treatment initiation, thus reducing the need 
for gastrectomy. Gastric DLBCL is treated with conventional 
regimens used for nodal DLBCL, such as R-CHOP,24 with 
excellent response. Attenuated dosage may be required in 
frail, elderly patients.9 Short courses of immune-chemother-
apy followed by involved-field radiation is the standard of 
care for limited stage nodal DLBCL. The 2 approaches, 
R-CHOP plus radiotherapy and R-CHOP, were compared in 
gastric DLBCL in a small retrospective study. Three to 4 
courses of R-CHOP plus radiotherapy yielded similar 3-year 
overall survival of over 90%, compared to 6 courses of 
R-CHOP.25 In patients who have already achieved complete 
remission with immunochemotherapy alone, involved field 
radiation may not be necessary.26 Our patient responded to 
chemotherapy but still had residual tumors; therefore, radia-
tion was pursued. He achieved pathological remission at the 
completion of radiation and remains well to date.
Conclusion
Gastric DLBCL is a rare disease and can present with nonspe-
cific symptoms such as weight loss and early satiety, as in our 
case. The diagnosis usually requires an EGD with biopsy. 
Controversies as to standard therapy exist. Chemotherapy and/
or immunotherapy, radiation, and surgery are all reasonable 
Figure 4. Significantly improved ulceration in the gastric body (arrow; A) and fundus (arrowhead; B).
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choices depending on patient presentation. For early stage dis-
ease, surgery is the most rational approach for curative resec-
tion, correct staging, and immediate treatment of bleeding or 
perforations. Adjuvant chemotherapy and radiotherapy are 
reasonable for advanced stage or residual disease. For stable 
cases where diagnosis is made by endoscopic biopsy, chemo-
therapy and radiotherapy can be an alternative primary, nonin-
vasive therapy of choice while surgery is used for residual 
tumor post chemotherapy/radiotherapy or for treatment of per-
foration. Chemotherapy and/or radiotherapy is the most ratio-
nal treatment for stage III and IV disease. Health care providers 
should maintain a high level of suspicion and consider gastric 
DLBCL as part of the differential diagnosis, especially in 
those with warning symptoms such as weight loss and early 
satiety with abnormal endoscopic findings.
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